• STOBOCLO^® (denosumab-bmwo) and OSENVELT^® (denosumab-bmwo) are approved by FDA for all indications of reference products PROLIA^® (denosumab) and XGEVA^® (denosumab) respectively^{[1], [2]}
• The FDA approval is based on robust clinical evidence, which show no clinically meaningful differences from the reference products
• With the FDA approval of STOBOCLO^® (denosumab-bmwo) and OSENVELT^® (denosumab-bmwo) Celltrion's biosimilar portfolio continues to grow, expanding treatment options to reach more patients

Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO^® (CT-P41, denosumab-bmwo) and OSENVELT^® (CT-P41, denosumab-bmwo), biosimilars referencing PROLIA^® (denosumab) and XGEVA^® (denosumab) respectively for all indications of reference products.^{[1], [2]}

"The approval of STOBOCLO and OSENVELT is another step forward in our efforts to deliver cost-effective and high-quality treatments that address critical unmet needs in osteoporosis-related fracture as well as cancer-related skeletal events," said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. "Patients deserve therapeutic options that have the potential to make real impacts on their care and their lives. We are committed to continuous innovation to meet these goals leveraging our experience and successful track record with biosimilar and novel biologics."

The FDA approval is based on robust clinical evidence, including results from Phase III clinical trials in postmenopausal women with osteoporosis designed to evaluate the efficacy, pharmacodynamics (PD), pharmacokinetics (PK), safety and immunogenicity of CT-P41 to reference denosumab. Study results demonstrated that CT-P41 had equivalent efficacy and PD to reference denosumab with similar PK and comparable safety and immunogenicity profiles.

"Denosumab is used to improve or protect bone health in patients with osteoporosis or those undergoing various cancer treatments and as a therapy for a lifetime for postmenopausal osteoporosis (PMO) patients," said Prof. Jean-Yves Reginster, Professor of Medicine, Protein Research Chair, Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia and Director WHO Collaborating Centre for Epidemiology of Musculoskeletal Health and Aging, Liège, Belgium. "Biosimilars have expanded into new therapeutic areas such as immunology, oncology and ophthalmology as they continue to offer significant cost-saving potential while expanding patient access. Having a denosumab product with a clinically proven track record in quality and safety is a valuable addition for my patients."

In accordance with a settlement agreement with Amgen Inc., STOBOCLO and OSENVELT are expected to be available in the U.S. in June 2025.